Cargando…
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan
Raloxifene was approved for chemoprevention against breast cancer among high-risk women in addition to tamoxifen by the US Food and Drug Administration. This study aims to evaluate cost-effectiveness of these agents under Japan's health system. A cost-effectiveness analysis with Markov model co...
Autores principales: | Kondo, M, Hoshi, S-L, Toi, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634700/ https://www.ncbi.nlm.nih.gov/pubmed/19142182 http://dx.doi.org/10.1038/sj.bjc.6604869 |
Ejemplares similares
-
Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015) -
Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
por: Bychkovsky, Brittany, et al.
Publicado: (2022) -
Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
por: Hind, D, et al.
Publicado: (2007) -
Breast cancer chemoprevention: beyond tamoxifen
por: Fabian, Carol J
Publicado: (2001) -
Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)